SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cell MedX Corp. – ‘10-Q’ for 2/28/21 – ‘EX-10.35’

On:  Friday, 4/9/21, at 1:53pm ET   ·   For:  2/28/21   ·   Accession #:  1393905-21-193   ·   File #:  0-54500

Previous ‘10-Q’:  ‘10-Q’ on 1/14/21 for 11/30/20   ·   Next:  ‘10-Q’ on 10/14/21 for 8/31/21   ·   Latest:  ‘10-Q’ on 4/15/24 for 2/29/24   ·   30 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/09/21  Cell MedX Corp.                   10-Q        2/28/21   56:2.8M                                   Empire Stock Transf… Inc

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Cell Medx Corp. - Form 10-Q SEC Filing              HTML    522K 
 2: EX-10.32    Loan December 14, 2020                              HTML     20K 
 3: EX-10.33    Loan December 23, 2020                              HTML     20K 
 4: EX-10.34    Loan January 21, 2021                               HTML     20K 
 5: EX-10.35    Loan February 16, 2021                              HTML     20K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     19K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     19K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     16K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     16K 
16: R1          Document and Entity Information                     HTML     64K 
17: R2          Condensed Consolidated Balance Sheets               HTML    100K 
18: R3          Condensed Consolidated Balance Sheets -             HTML     23K 
                Parenthetical                                                    
19: R4          Condensed Consolidated Statements of Operations     HTML     86K 
20: R5          Condensed Consolidated Statement of Stockholders'   HTML     85K 
                Deficit                                                          
21: R6          Condensed Consolidated Statements of Cash Flows     HTML     92K 
22: R7          Organization and Nature of Operations               HTML     23K 
23: R8          Related Party Transactions Disclosure               HTML     35K 
24: R9          Inventory Disclosure                                HTML     19K 
25: R10         Other Current Assets Disclosure                     HTML     18K 
26: R11         Equipment Disclosure                                HTML     24K 
27: R12         Revenue Disclosure                                  HTML     29K 
28: R13         Notes and Advances Payable Disclosure               HTML     48K 
29: R14         Share Capital Disclosure                            HTML     49K 
30: R15         Related Party Transactions Disclosure: Schedule of  HTML     26K 
                Amounts Due to Related Parties (Tables)                          
31: R16         Related Party Transactions Disclosure: Schedule of  HTML     25K 
                Transactions with Related Parties (Tables)                       
32: R17         Equipment Disclosure: Change in book value of the   HTML     24K 
                equipment (Tables)                                               
33: R18         Revenue Disclosure: Schedule of Revenue and         HTML     29K 
                Associated Costs (Tables)                                        
34: R19         Notes and Advances Payable Disclosure: Schedule of  HTML     38K 
                Short-term Loans and Advances Outstanding (Tables)               
35: R20         Share Capital Disclosure: Schedule of Stock Option  HTML     26K 
                Activity (Tables)                                                
36: R21         Share Capital Disclosure: Schedule of Stock         HTML     22K 
                Options Outstanding (Tables)                                     
37: R22         Share Capital Disclosure: Schedule of Warrant       HTML     26K 
                Activity (Tables)                                                
38: R23         Share Capital Disclosure: Schedule of Warrant       HTML     24K 
                Details (Tables)                                                 
39: R24         Organization and Nature of Operations (Details)     HTML     20K 
40: R25         Related Party Transactions Disclosure: Schedule of  HTML     33K 
                Amounts Due to Related Parties (Details)                         
41: R26         Related Party Transactions Disclosure: Schedule of  HTML     29K 
                Transactions with Related Parties (Details)                      
42: R27         Inventory Disclosure (Details)                      HTML     21K 
43: R28         Other Current Assets Disclosure (Details)           HTML     21K 
44: R29         Equipment Disclosure: Change in book value of the   HTML     27K 
                equipment (Details)                                              
45: R30         Revenue Disclosure: Schedule of Revenue and         HTML     43K 
                Associated Costs (Details)                                       
46: R31         Notes and Advances Payable Disclosure: Schedule of  HTML     44K 
                Short-term Loans and Advances Outstanding                        
                (Details)                                                        
47: R32         Notes and Advances Payable Disclosure (Details)     HTML     58K 
48: R33         Share Capital Disclosure (Details)                  HTML     42K 
49: R34         Share Capital Disclosure: Schedule of Stock Option  HTML     31K 
                Activity (Details)                                               
50: R35         Share Capital Disclosure: Schedule of Stock         HTML     27K 
                Options Outstanding (Details)                                    
51: R36         Share Capital Disclosure: Schedule of Warrant       HTML     25K 
                Activity (Details)                                               
52: R37         Share Capital Disclosure: Schedule of Warrant       HTML     31K 
                Details (Details)                                                
54: XML         IDEA XML File -- Filing Summary                      XML     91K 
15: XML         XBRL Instance -- cmxc-20210228_htm                   XML    765K 
53: EXCEL       IDEA Workbook of Financial Reports                  XLSX     46K 
10: EX-101.CAL  XBRL Calculations -- cmxc-20210228_cal               XML     62K 
11: EX-101.DEF  XBRL Definitions -- cmxc-20210228_def                XML    254K 
12: EX-101.LAB  XBRL Labels -- cmxc-20210228_lab                     XML    451K 
13: EX-101.PRE  XBRL Presentations -- cmxc-20210228_pre              XML    384K 
14: EX-101.SCH  XBRL Schema -- cmxc-20210228                         XSD    143K 
55: JSON        XBRL Instance as JSON Data -- MetaLinks              175±   247K 
56: ZIP         XBRL Zipped Folder -- 0001393905-21-000193-xbrl      Zip     89K 


‘EX-10.35’   —   Loan February 16, 2021


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  LOAN February 16, 2021  

 

LOAN

AGREEMENT

February 16, 2021

 

Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$30,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on February 16, 2021.

 

The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from February 16, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.

 

The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.

 

LENDER

BORROWER

Rain Communications Corp.

Cell MedX Corp.

 

 

Per:

Per:

 

 

 

 

/s/ Ralph Biggar

/s/  Yanika Silina

Ralph Biggar, President

Yanika Silina, CFO

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

PROMISSORY NOTE

 

Principal Amount: USD$30,000

February 16, 2021

 

 

FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Rain Communications Corp. (the “Lender”) the sum of $30,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from February 16, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.

 

For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.

 

The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.

 

The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.

 

 

BORROWER

Cell MedX Corp.

 

Per:

 

 

/s/ Yanika Silina

Yanika Silina, CFO

 

 

 

 

 

 

 

 

 

 

 

 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:4/9/21424B3
For Period end:2/28/21
2/16/214
 List all Filings 


15 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/15/24  Cell MedX Corp.                   10-Q        2/29/24   53:2.7M                                   Empire Stock Transf… Inc
 1/16/24  Cell MedX Corp.                   10-Q       11/30/23   46:2.3M                                   Empire Stock Transf… Inc
10/16/23  Cell MedX Corp.                   10-Q        8/31/23   42:1.9M                                   Empire Stock Transf… Inc
 9/01/23  Cell MedX Corp.                   10-K        5/31/23   73:3.2M                                   Empire Stock Transf… Inc
 6/29/23  Cell MedX Corp.                   10-Q        2/28/23   53:2.5M                                   Empire Stock Transf… Inc
 5/19/23  Cell MedX Corp.                   10-Q       11/30/22   53:2.4M                                   Empire Stock Transf… Inc
 4/19/23  Cell MedX Corp.                   10-Q        8/31/22   51:2.2M                                   Empire Stock Transf… Inc
 4/07/23  Cell MedX Corp.                   10-K        5/31/22   90:3.6M                                   Empire Stock Transf… Inc
 4/11/22  Cell MedX Corp.                   10-Q        2/28/22   56:2.5M                                   Empire Stock Transf… Inc
 1/12/22  Cell MedX Corp.                   10-Q       11/30/21   54:2.4M                                   Empire Stock Transf… Inc
10/14/21  Cell MedX Corp.                   424B3                  1:365K                                   Empire Stock Transf… Inc
10/14/21  Cell MedX Corp.                   10-Q        8/31/21   50:2.2M                                   Empire Stock Transf… Inc
10/12/21  Cell MedX Corp.                   424B3                  1:705K                                   Empire Stock Transf… Inc
 8/30/21  Cell MedX Corp.                   10-K        5/31/21   83:3.7M                                   Empire Stock Transf… Inc
 4/09/21  Cell MedX Corp.                   424B3                  1:501K                                   Empire Stock Transf… Inc


15 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/14/21  Cell MedX Corp.                   10-Q       11/30/20   53:2M                                     Empire Stock Transf… Inc
 9/15/20  Cell MedX Corp.                   10-K        5/31/20   84:2.9M                                   Empire Stock Transf… Inc
 4/14/20  Cell MedX Corp.                   10-Q        2/29/20   67:2.2M                                   Empire Stock Transf… Inc
 1/31/20  Cell MedX Corp.                   8-K:1,9     1/29/20    3:69K                                    Empire Stock Transf… Inc
 1/14/20  Cell MedX Corp.                   10-Q       11/30/19   65:2.2M                                   Empire Stock Transf… Inc
12/31/18  Cell MedX Corp.                   8-K:1,3,9  12/27/18    3:248K                                   Empire Stock Transf… Inc
 9/13/18  Cell MedX Corp.                   10-K        5/31/18   85:3M                                     Empire Stock Transf… Inc
10/17/17  Cell MedX Corp.                   10-Q        8/31/17   59:2.2M                                   Empire Stock Transf… Inc
 8/11/15  Cell MedX Corp.                   8-K:5,9     8/11/15    3:172K                                   Ideal Connection, Inc/FA
11/18/14  Cell MedX Corp.                   8-K:1,9    11/13/14    2:48K                                    Ideal Connection, Inc/FA
11/03/14  Cell MedX Corp.                   8-K:1,9    10/28/14    2:60K                                    Ideal Connection, Inc/FA
10/17/14  Cell MedX Corp.                   8-K:1,9    10/16/14    3:407K                                   Ideal Connection, Inc/FA
10/09/14  Cell MedX Corp.                   10-Q        8/31/14   37:2.9M                                   Ideal Connection, Inc/FA
10/13/10  Cell MedX Corp.                   S-1/A                  8:1.2M                                   Toppan Merrill/FA
 7/13/10  Cell MedX Corp.                   S-1                   11:921K                                   Toppan Merrill/FA
Top
Filing Submission 0001393905-21-000193   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 9:55:58.3am ET